167 related articles for article (PubMed ID: 22083486)
41. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
Cross SA; Scott LJ
Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
[TBL] [Abstract][Full Text] [Related]
42. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.
Andes DR; Diekema DJ; Pfaller MA; Marchillo K; Bohrmueller J
Antimicrob Agents Chemother; 2008 Oct; 52(10):3497-503. PubMed ID: 18625768
[TBL] [Abstract][Full Text] [Related]
43. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
44. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
Albano E; Azie N; Roy M; Townsend R; Arrieta A
J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
[TBL] [Abstract][Full Text] [Related]
46. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González M; Carlos Montejo-González J
Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
[TBL] [Abstract][Full Text] [Related]
47. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
[TBL] [Abstract][Full Text] [Related]
48. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.
Yanni SB; Smith PB; Benjamin DK; Augustijns PF; Thakker DR; Annaert PP
Biopharm Drug Dispos; 2011 May; 32(4):222-32. PubMed ID: 21449041
[TBL] [Abstract][Full Text] [Related]
49. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
[TBL] [Abstract][Full Text] [Related]
50. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
[TBL] [Abstract][Full Text] [Related]
51. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!
Gumbo T
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S635-42. PubMed ID: 26567282
[TBL] [Abstract][Full Text] [Related]
52. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Andes D; Diekema DJ; Pfaller MA; Bohrmuller J; Marchillo K; Lepak A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2497-506. PubMed ID: 20385855
[TBL] [Abstract][Full Text] [Related]
53. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
Garnacho-Montero J; Jiménez Parrilla F
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
[TBL] [Abstract][Full Text] [Related]
54. Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.
Slater JL; Howard SJ; Sharp A; Goodwin J; Gregson LM; Alastruey-Izquierdo A; Arendrup MC; Warn PA; Perlin DS; Hope WW
Antimicrob Agents Chemother; 2011 Jul; 55(7):3075-83. PubMed ID: 21502627
[TBL] [Abstract][Full Text] [Related]
55. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
Mizuno H; Sawa M; Yanada M; Shirahata M; Watanabe M; Kato T; Nagai H; Ozawa Y; Morishita T; Tsuzuki M; Goto E; Tsujimura A; Suzuki R; Atsuta Y; Emi N; Naoe T
Int J Hematol; 2013 Aug; 98(2):231-6. PubMed ID: 23857638
[TBL] [Abstract][Full Text] [Related]
56. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
Jullien V; Azoulay E; Schwebel C; Le Saux T; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Cour M; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Wolff M; Timsit JF;
J Antimicrob Chemother; 2017 Jan; 72(1):181-189. PubMed ID: 27609051
[TBL] [Abstract][Full Text] [Related]
57. Antifungal activity of micafungin in serum.
Ishikawa J; Maeda T; Matsumura I; Yasumi M; Ujiie H; Masaie H; Nakazawa T; Mochizuki N; Kishino S; Kanakura Y
Antimicrob Agents Chemother; 2009 Oct; 53(10):4559-62. PubMed ID: 19687246
[TBL] [Abstract][Full Text] [Related]
58. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis.
Grau S; Luque S; Campillo N; Samsó E; Rodríguez U; García-Bernedo CA; Salas E; Sharma R; Hope WW; Roberts JA
J Antimicrob Chemother; 2015 Oct; 70(10):2854-61. PubMed ID: 26180134
[TBL] [Abstract][Full Text] [Related]
59. Safety of high-dose micafungin for patients with hematological diseases.
Yamazaki S; Nakamura F; Yoshimi A; Ichikawa M; Nannya Y; Kurokawa M
Leuk Lymphoma; 2014 Nov; 55(11):2572-6. PubMed ID: 24460099
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
